Senators press Novo Nordisk CEO on why Ozempic and Wegovy cost less abroad
Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for brand-name prescriptions.
Novo Nordisk CEO grilled by Congress over Ozempic, Wegovy prices in US
For the millions of people living with diabetes or obesity, drugs like Ozempic and Wegovy can significantly improve their health.
‘You’re hiding behind your opaqueness’: Senators question Novo Nordisk CEO over high cost of Ozempic, Wegovy
Bipartisan lawmakers grilled Novo Nordisk CEO Lars Fruergaard Jørgensen in a Senate hearing in an attempt to pick apart the high cost of GLP-1 drugs.
Ozempic maker's CEO grilled over price of weight loss drugs
The CEO of the company that makes Ozempic faced a Bernie Sanders-led Senate hearing on Tuesday.
Ozempic CEO agrees to discuss lower prices for blockbuster weight loss drugs
Is Ozempic and Wegovy maker Novo Nordisk helping Americans save taxpayer money or ripping them off? The company's CEO testified on Capitol Hill Tuesday.
Ozempic maker testifies before Senate committee on weight loss drug prices
Novo Nordisk CEO Lars Fruergaard Jørgensen testified before the Senate Health, Education, Labor and Pension committee on Tuesday.
Ozempic maker's CEO blames insurance companies for weight-loss drug prices
The chief executive of the company behind Ozempic and Wegovy blamed insurers and middlemen for the high costs of weight-loss drugs in the U.S. during a congressional testimony on Tuesday. Why it matters: Lars Fruergaard Jørgensen,
Weight-loss drugmaker CEO faces questions over high costs
U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North Carolina cut the weight-loss drugs from its state health plan.
Ozempic producer CEO in hot seat in Senate hearing over cost of weight loss drug
Senators grilled Novo Nordisk CEO Lars Jørgensen Tuesday at a hearing over the costs of Ozempic, Wegovy and similar weight loss drugs. The drugs have risen in popularity for diabetic patients and others looking to combat obesity since they were approved,
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...
Kennebec Journal1hOpinion
Commentary: Who’s really keeping Ozempic and Wegovy prices so high?
On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard ...
Novo Nordisk stock closes lower, analyst warns about Wegovy sales
Shares of Novo Nordisk (NVO) slipped on Friday following a note from JPMorgan's Richard Vosser. Vosser warned that the ...
Why does Ozempic cost so much? Senators grilled Novo Nordisk CEO for answers.
Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.
Novo Nordisk CEO spars with lawmakers over Ozempic, Wegovy prices
The CEO of Novo Nordisk faced pointed questions about the cost of Ozempic and Wegovy on Capitol Hill Tuesday, as lawmakers ...
Novo Nordisk’s Wegovy-Fueled Gains Fading as Analyst Doubts Grow
The obesity-drug hype that fueled huge gains in Novo Nordisk A/S looks to be running out of steam.Most Read from ...
Benefits Pro2d
'Stop ripping us off,' says Sen. Sanders, but Novo CEO blames PBMs for high Wegovy prices
Novo Nordisk has a price fix solution for uninsured patients with diabetes, but not for HSA holders or people with normal ...
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on ...
Vermont Business Magazine3d
Sanders leads HELP Committee hearing with Novo Nordisk CEO on Ozempic and Wegovy prices
Chairman of the Senate Committee on Health, Education, Labor, and Pensions (HELP), today led the committee in a hearing to ...